ReviewFrontiers in allergy2026
Bridging innovation and risk: the missing role of validated risk-stratification in IgE-mediated food allergy management.
Review in Frontiers in allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over the last decade, the prevalence of IgE-mediated food allergies has increased, alongside therapeutic innovations such as oral immunotherapy (OIT), omalizumab, combination approaches, intranasal epinephrine, and emerging biomarker-guided strategies. This mini review synthesizes evidence published between 2019 and 2025 and evaluates how these advances intersect with persistent safety and clinical decision-making challenges. Although these therapies demonstrate promising efficacy, validated risk-stratification tools capable of guiding individual treatment selection are lacking. The proposed conceptual framework illustrates how patient characteristics, biomarkers, and treatment-specific risks may ultimately support individualized therapeutic decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.